256 related articles for article (PubMed ID: 19563489)
1. Susceptibility profile of vaginal isolates of Candida albicans prior to and following fluconazole introduction - impact of two decades.
Bulik CC; Sobel JD; Nailor MD
Mycoses; 2011 Jan; 54(1):34-8. PubMed ID: 19563489
[TBL] [Abstract][Full Text] [Related]
2. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.
Sobel JD; Ohmit SE; Schuman P; Klein RS; Mayer K; Duerr A; Vazquez JA; Rampalo A;
J Infect Dis; 2001 Jan; 183(2):286-93. PubMed ID: 11204125
[TBL] [Abstract][Full Text] [Related]
3. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
Oz Y; Akşit F; Kiraz N; Kiremitçi A
Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
[TBL] [Abstract][Full Text] [Related]
4. [In vitro biofilm formation and relationship with antifungal resistance of Candida spp. isolated from vaginal and intrauterine device string samples of women with vaginal complaints].
Calışkan S; Keçeli Özcan S; Cınar S; Corakçı A; Calışkan E
Mikrobiyol Bul; 2011 Oct; 45(4):697-706. PubMed ID: 22090300
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents.
Favel A; Michel-Nguyen A; Datry A; Challier S; Leclerc F; Chastin C; Fallague K; Regli P
J Antimicrob Chemother; 2004 Mar; 53(3):526-9. PubMed ID: 14963064
[TBL] [Abstract][Full Text] [Related]
6. Influence of human serum on antifungal pharmacodynamics with Candida albicans.
Zhanel GG; Saunders DG; Hoban DJ; Karlowsky JA
Antimicrob Agents Chemother; 2001 Jul; 45(7):2018-22. PubMed ID: 11408217
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of broth microdilution and E-test methods for the antifungal susceptibility testing of Candida spp. strains isolated from blood cultures].
Ozcan SK; Mutlu B; Dündar D; Willke A
Mikrobiyol Bul; 2010 Apr; 44(2):263-71. PubMed ID: 20549961
[TBL] [Abstract][Full Text] [Related]
8. [Vaginal candidiasis: etiology and sensitivity profile to antifungal agents in clinical use].
Saporiti AM; Gómez D; Levalle S; Galeano M; Davel G; Vivot W; Rodero L
Rev Argent Microbiol; 2001; 33(4):217-22. PubMed ID: 11833253
[TBL] [Abstract][Full Text] [Related]
9. [Molecular epidemiologic surveillance and antifungal agent sensitivity of Candida albicans isolated from anesthesia intensive care units].
Gülay Z; Ergon C; Ozkütük A; Yücesoy M; Biçmen M
Mikrobiyol Bul; 2002; 36(3-4):309-16. PubMed ID: 12838665
[TBL] [Abstract][Full Text] [Related]
10. Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis.
Cernicka J; Subik J
Int J Antimicrob Agents; 2006 May; 27(5):403-8. PubMed ID: 16621465
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of voriconazole against Candida species isolated in Taiwan.
Yang YL; Cheng HH; Lo HJ
Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility and trailing growth of Candida albicans to fluconazole: results of a Korean multicentre study.
Lee MK; Kim HR; Kang JO; Kim MN; Kim EC; Kim JS; Kim JJ; Park YJ; Song W; Shin JH; Lee KM; Lee NY; Lee M; Lee WG; Lee CK; Lee HJ; Chang CL; Choi TY
Mycoses; 2007 Mar; 50(2):148-9. PubMed ID: 17305780
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
Swinne D; Watelle M; Van der Flaes M; Nolard N
Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
[TBL] [Abstract][Full Text] [Related]
14. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production.
Tortorano AM; Prigitano A; Biraghi E; Viviani MA;
J Antimicrob Chemother; 2005 Oct; 56(4):777-9. PubMed ID: 16144871
[TBL] [Abstract][Full Text] [Related]
15. Activated lactoferrin and fluconazole synergism against Candida albicans and Candida glabrata vaginal isolates.
Naidu AS; Fowler RS; Martinez C; Chen J; Tulpinski J
J Reprod Med; 2004 Oct; 49(10):800-7. PubMed ID: 15568403
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of oral Candida to seven antifungal agents.
Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
[TBL] [Abstract][Full Text] [Related]
17. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans.
De Logu A; Saddi M; Cardia MC; Borgna R; Sanna C; Saddi B; Maccioni E
J Antimicrob Chemother; 2005 May; 55(5):692-8. PubMed ID: 15772140
[TBL] [Abstract][Full Text] [Related]
19. Impact of endpoint definition on the outcome of antifungal susceptibility tests with Candida species: 24- versus 48-h incubation and 50 versus 80% reduction in growth.
St-Germain G
Mycoses; 2001; 44(1-2):37-45. PubMed ID: 11398639
[TBL] [Abstract][Full Text] [Related]
20. Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients.
Chryssanthou E; Torssander J; Petrini B
Scand J Infect Dis; 1995; 27(4):391-5. PubMed ID: 8658076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
